HomeArticle

Qiming Venture Partners gave him his first sum of money.

投资界2026-11-16 09:23
CataX AI makes its debut.

The battlefield of AI drug development is shifting from molecules to clinical trials.

Investment Circle has learned that CataX AI has recently completed its seed round financing, with exclusive investment from Qiming Venture Partners. Unlike previous AI pharmaceutical companies that focused on drug discovery, this AI-native biotech, established only 4 months ago, does not engage in target and molecule discovery, but leverages Agents to accelerate the early clinical development of new drugs.

The founder behind it, Wang Zilong, is a post-90s generation. When he was a high school freshman, he obtained the qualification for guaranteed admission by winning the first prize in the National Biology Olympiad. During high school, he won four first prizes in three competitions: biology, physics, and informatics. Later, he chose to study the 8-year clinical medicine program at Fudan University, and finally obtained a doctorate in oncology. After that, he served as CTO and Chief Medical Officer of an AI medical technology company, and was selected into the Forbes 30 Under 30 list; he then joined Microsoft Research Asia, becoming the only researcher with a medical background in MSRA who focuses on medical AI. After several cross-sector transitions, he now steps into the drug development field in person.

Talking about this entrepreneurship, Wang Zilong traced from his medical study experience to the Agent wave, with a consistent thread running through: "Medicine determines why we set off, and AI determines how we should proceed." All the way along, what he has always wanted to shorten is the distance between technology and patients.

The Post-90s AI Genius Grows into a Doctor of Medicine

Decided to Devote Himself to the AIDD Wave

The story starts with Wang Zilong.

Born in Qinhuangdao, Hebei in 1991, he started winning multiple first prizes in national competitions including biology, physics, and informatics from his first year of high school, and got the guaranteed admission qualification very early. Although he was extremely obsessed with computer science, he made a seemingly counterintuitive choice: to enter Fudan University to pursue the 8-year clinical medicine program.

He had his own considerations: computer science is fully open to self-learning, while medicine cannot be learned out of thin air, and requires systematic formal training. "No one can walk into the operating room without valid credentials. But maybe one day, AI can really replace doctors and drug developers?"

At Fudan University, Wang Zilong studied medicine while auditing computer science courses. He compared interdisciplinary learning to sailing: stepping into an unfamiliar field is like a dark, boundless sea, and the intersection between different disciplines is a "precious freshwater island". It takes time to find it. "Don't rush, you will find it eventually if you are patient."

His experience of clinical rotations and internship at Tencent showed him another possibility. A department can perform more than a dozen surgeries in a non-stop day; while at Tencent, the team's product can reach about 100,000 users once launched. He began to think about how to bring technology into medical care to benefit more patients.

After graduation, Wang Zilong joined the AI medical enterprise VoxelCloud, and took on the positions of CTO and Chief Medical Officer at the age of only 28. In that period of entrepreneurial practice, he led the team to promote a prospective multi-center study covering 155 centers across China with more than 47,000 subjects, and obtained one of the early NMPA Class III medical AI device registration certificates in China. He was successively selected into the Forbes 30 Under 30 list and the Hurun U30 Entrepreneur Leaders list.

It was the time when the large model wave swept across the industry. In 2023, Wang Zilong chose to return to the highland of scientific research and served as a senior researcher at Microsoft Research Asia (MSRA), focusing on medical foundation models, autonomous agents and human-AI collaboration, and his related research won more than 20,000 stars on GitHub.

The turning point came at the beginning of this year, when successive Agent products brought a "leap of faith". Previously, Wang Zilong participated in a research on visually impaired programmers, observing how they use AI tools to program and review code. As the paper progressed, the real world was rewritten at a faster speed. Even when he wrote code himself, he almost no longer reviewed it line by line.

"Medicine determines why we set off, and AI determines how we should proceed." The change in the division of labor between humans and AI made him think of the reality of the pharmaceutical industry.

Nowadays, new drug clinical development still has a strong industrial assembly line feature: to advance a pipeline, more than ten functional departments including medicine, registration, operation, data, and biostatistics need to cooperate with each other. Even modifying a conventional report is accompanied by tedious cross-departmental meetings and document circulation.

"If agents are deeply involved from the very first day, what kind of biopharmaceutical company would that be?" With this question, Wang Zilong resolutely left Microsoft and started his own business.

Qiming Venture Partners Incubates an AI-Native Pharmaceutical Enterprise

"Wang Zilong has extremely strong entrepreneurial passion." Chen Kan, Partner and Co-Head of Healthcare Innovation at Qiming Venture Partners, recalled his first impression, "There are many people in the market who understand AI, and many people with medical education background, but people who not only conduct cutting-edge medical AI research at Microsoft, but also receive systematic clinical medicine training, and are eager to go to the front line to do practical things, are extremely rare."

This spring, introduced by a Fudan University alumnus, Wang Zilong met Chen Kan.

At that time, Wang Zilong only had a rough framework of "embedding Agents into pharmaceutical development" in his mind, and had not even finished writing the business plan. But the two talked for hours around technology evolution and new drug R&D, and reached a consensus on many underlying judgments.

As one of the earliest investment institutions in China that laid out AI pharmaceutical tracks, Qiming Venture Partners previously invested in early drug discovery companies such as Insilico Medicine. In Chen Kan's view, the application of AI in target discovery and molecular design stages has been relatively mature, and now the bottleneck of the entire pharmaceutical industry has shifted to the downstream.

The R&D of a new drug often takes a decade and costs billions of dollars. Among them, early drug discovery only accounts for about 20% of the cost and time, and the remaining 80% of the weight falls on the clinical development stage. In the past few years, the output of preclinical new drug molecules (PCC) in China has accounted for 44% of the global total, and there is an urgent need for a cost-effective channel to cross the lifeline of "human proof of concept (PoC)".

"If human beings stop discovering all new drug molecules today, the stock accumulated in laboratories alone is enough for the global clinical system to digest for a full decade." In Chen Kan's view, reconstructing clinical trials with agents is the only way to reduce costs. However, for traditional pharmaceutical companies to break through the barriers of numerous functional departments through AI is no different from overthrowing the entire old system. Instead of fighting against huge inertia, it is better to start from scratch.

Subsequently, Qiming Venture Partners decided to make exclusive investment in the seed round, and co-incubated this new company with Wang Zilong. Driven and introduced by Qiming Venture Partners, Jiang Zhemin, who has more than ten years of clinical operation experience in companies such as Tigermed and BeiGene, joined as co-founder and CDO, filling the key link of clinical implementation.

In July 2026, CataX AI was established in Shanghai. "Cata" is taken from the word Catalyst, which means accelerating new drug R&D; the "X" logo is formed by the intersection of green DNA double helix and blue chip circuits, implying the exploration of unknown diseases, and also embodying the expectation of 10x efficiency.

The company targets preclinical and early clinical pipelines, and plans to hold corresponding rights and interests through in-licensing or co-development to advance early clinical proof of concept (PoC). For projects with positive human evidence, it will seek out-licensing to partners with capabilities for subsequent development and commercialization to take over.

To undertake these pipelines, the team has explored the "Clinical-of-One" model. One clinical development lead oversees the project, coordinating Agents and external experts. Literature research, document drafting, and data processing are completed with the participation of Agents, while key decisions are made by humans.

Admittedly, medical verification cannot go against the harsh objective laws: if a clinical follow-up takes one year, AI cannot shorten the time out of thin air. The so-called efficiency of "10x Biotech" is to invest resources in more valuable clinical verifications through precise asset screening and reduction of artificial internal friction.

One Person Oversees N Pipelines: A Sample of China's Future Pharmaceutical Enterprises Emerges

"Pharmaceutical companies in the future are destined to evolve towards this organizational paradigm." Chen Kan regards the exploration of CataX AI as a pathfinder for the industry.

In his view, the reshaping of R&D and underlying division of labor by Agents will eventually penetrate into the entire industry, but this cannot happen in a vacuum, and requires the entire ecosystem to move forward together. The internal innovation of a company ultimately needs to connect with hospitals, partners and the regulatory system.

This exploration coincides with the window period when China's innovative drugs go global. Chen Kan observed that overseas pharmaceutical companies' attention to Chinese assets has shifted from price advantage to asset quality. Some promising early projects still cannot move forward due to insufficient funds. For newly established biotechs, opportunities to participate in global R&D lie in these links that are yet to be connected.

Looking back at the present, the most realistic challenge for CataX AI is how to expand this model from the initial few people to a larger scale.

"I cannot replicate ten versions of myself." Wang Zilong admitted that the leads overseeing the pipelines at present need to have both in-depth clinical cognition and AI thinking. It is not easy to find such people. If every project relies on the experience of a small number of people, this model will be difficult to be adopted by more teams.

Wang Zilong finds the solution to the breakthrough in the precipitation of "organizational experience".

Public medical literature can be learned by large models, but much experience in clinical trial R&D is hidden in the specific trade-offs of daily work. Why experts require the protocol to be modified at a certain point, how the team decides to continue or stop investment according to new data, Wang Zilong hopes to retain the basis behind these practical judgments.

In his vision, feedback from external experts, the team's decision-making trajectory and subsequent results are all stored in the same system for reference by subsequent projects. After one development cycle is completed, experience can continue to accumulate, and new clinical leads can also follow the existing logic, so that this model will gradually reduce its dependence on a small number of cross-sector talents.

This focus on the transmission of knowledge and experience exactly echoes Wang Zilong's thinking on "cross-discipline".

"We are drawing boundaries for ourselves." Wang Zilong mentioned Liu Cixin's *The Village Teacher*. Memory cannot be inherited, and although knowledge can be passed on, everyone still needs to go through a long period of learning to reach the place predecessors have arrived. He expects Agents to become the "external brain", helping people access broader knowledge and extend exploration beyond existing professional boundaries.

Of course, there are still many tough battles to fight to turn the blueprint into daily practice. Wang Zilong said that the team is reorganizing the clinical development process, coordinating technical systems, risk control and regulatory requirements. The performance of Agents in asset research also needs to be continuously verified in subsequent development.

"New drug R&D is a long marathon relay race. The hardest part is never the start, but how to smoothly and efficiently pass every baton to the finish line." In Wang Zilong's view, the reconstruction of technology and organization is nothing but returning time to science, so that drugs can deliver hope one step earlier.

This article is from the WeChat Official Account "Investment Circle" (ID: pedaily2012), written by Wang Lu, authorized for release by 36Kr.